- POAI is leveraging the potential of AI and smart tumor profiling to predict tumor drug response
- TumorGenesis is developing innovative techniques for growing tumors in laboratory settings
- Helomics uses vital information from patients’ own living tumors to assist oncologists in selecting the most effective treatments
Predictive Oncology Inc. (NASDAQ: POAI) is harnessing the power of artificial intelligence (AI) and rich information from patients’ own tumors to improve outcomes for cancer patients. Predictive Oncology applies its proprietary smart tumor profiling and AI platform to extensive genomic and biomarker patient datasets in order to predict tumor drug response and improve clinical outcomes for cancer patients.
Last year, POAI, then known as Precision Therapeutics, formed TumorGenesis to focus on innovative ways to create improved patient derived (PDx) tumor models. Currently, TumorGenesis is working on developing new techniques for growing tumors in the lab to generate more relevant models of the tumors that can be used to test drugs for personalized therapy or aid in development of new medications.
The approach is designed to grow tumors in the lab by providing an environment that closely mimics the human body, through the use of chemistry, biology, mechanics and cell nutrients. In addition to this exclusive technology being quicker and more affordable than existing PDx animal models, researchers anticipate that the approach will better replicate the characteristics of tumors. Initially, the company plans to develop PDx models for multiple myeloma, triple-negative breast cancer and ovarian cancer, but Predictive is expecting the technology to ultimately benefit oncologists who are investigating other cancer areas as well, including liver, pancreatic, lung and colon.
To validate these new tumor models, TumorGenesis is working closely with Predictive’s Helomics team and is also actively looking for external partners that could potentially benefit from these innovative technologies and advance research.
Helomics is dedicated to improving the standard of care for cancer patients by using vital information provided by patients’ own living tumors to assist oncologists in selecting the most effective treatments. Helomics uses its exclusive tumor drug-response profiling platform, together with the latest next-generation sequencing (NGS)-based genomic profiling and its vast knowledgebase of 150,000 tumors, to provide additional context to create a valuable predictive tool for clinicians and researchers. This approach is rooted in the company’s belief that capturing this invaluable patient-specific information in conjunction with such a huge historical database provides a more functional approach to precision medicine than relying on genomics alone.
In a page straight out of Sun Tzu’s The Art of War, Predictive Oncology is helping oncologists and researchers “know the enemy” by harnessing rich information from patient tumors using artificial intelligence to build predictive models of tumor drug response. Predictive Oncology is working with the pharmaceutical, diagnostic and biotech industries to use these models to both improve the development of new drugs and help clinicians individualize therapy. For investors, Predictive Oncology offers the possibility for significant ROI, as it has already amassed (through its acquisition of Helomics) a huge cancer dataset that can be mined to provide valuable insights to improve treatment.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com